GlobeNewswire Inc | Nov 1, 2021 07:00AM EDT

November 01, 2021

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd.(Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2021 financial results and operational highlights before the open of the U.S. stock markets onWednesday, November 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Timeto discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, November 10, 2021Time: 8:30 AM Eastern TimeUnited States: +1 877 870 9135Israel: +972 1809 213-985International: +44 (0) 2071 928338Conference ID: 4585862Webcast: https://edge.media-server.com/mmc/p/5rbkqsbe

AboutPolyPidPolyPid Ltd. (Nasdaq: PYPD) is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPids proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPids lead product candidate D-PLEX100is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

For additional company information, please visit http://www.polypid.comand follow us onTwitter andLinkedIn.

Contacts:PolyPid, Ltd.Dikla Czaczkes AkselbradEVP & CFOTel: +972-747195700

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com